Updated:
BIOXYTRAN, INC
BIOXYTRAN, INC is listed in the Altss directory; the profile covers headquarters, registration, AUM band and key contacts for private-markets fundraising.
Overview
Developing new drugs under FDA regulation for hypoxia brain and heart ischemia and viral infection like coronavirus and influenza.
General information
Principals
David Platt
Chief Executive Officer
Michael Sheikh
Chief Financial Officer
Sector focus
Frequently asked questions
What is Bioxytran's lead drug candidate?
The lead asset is BXT-25, a brain-tropic oxygen carrier designed to treat acute ischemic stroke by transporting oxygen across the blood-brain barrier. The firm has also explored additional applications for its carbohydrate-based platform in wound care and antiviral indications.
How is Bioxytran funded as a clinical-stage company?
Bioxytran does not operate with a traditional venture capital backing. It has remained publicly traded on OTC markets and raises capital through equity financings and convertible instruments, making its financial structure atypical for a pre-revenue biotech.
Does Bioxytran have any partnership with major pharmaceutical companies?
There is no public record of a partnership with a major pharmaceutical firm. Bioxytran's disclosed collaborations have primarily involved contract research organizations and academic institutions for its clinical and preclinical work.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: